News & Press Releases Swedish

Animal Care-verksamheten går mot ett starkt fjärde kvartal 2024 försäljningsmässigt

Scandinavian ChemoTechs Animal Care-verksamhet fortsätter växa och försäljningen i kvartal fyra uppgår redan till ca 1500 KSEK och beräknas överstiga 6000 KSEK för helåret 2024. Försäljningen under kvartal fyra avser både installationer av vetIQure™ TSE-system samt försäljning av behandlings-kits. Vi ser en ökande försäljning till befintliga kunder som återkommer med köp av förbrukningsmaterial, vilket är…

Read more

ChemoTechs Animal Care inleder strategiskt samarbete med veterinäruniversitets sjukhus för hästmedicin i Norge

Scandinavian ChemoTech AB:s dotterbolag, dedikerat till Animal Care, har inlett ett kliniskt samarbete med Norges Biovetenskapliga Universitetssjukhus (NMBU) för hästmedicin. Efter en omfattande utvärderingsperiod har NMBU:s häst-team, under ledning av professor och DVM Cathrine Fjordbakk, beslutat att integrera behandlingar med ChemoTechs tumörspecifika elektroporation (TSE) i sina rutinmässiga behandlingserbjudanden. Detta partnerskaps målsättning är att sätta nya…

Read more

Scandinavian ChemoTech AB publicerar delårsrapport för januari – september 2024

Scandinavian ChemoTech AB (publ) publicerar härmed delårsrapport för Q3 2024. Rapporten finns bifogad till detta pressmeddelande och kan även hämtas från Bolagets hemsida (https://www.chemotech.se/investor-relations/financial-reports/)

Read more

–

Read all news in Swedish

News & Press Releases English

Scandinavian ChemoTech’s Animal Care is heading towards a strong fourth quarter 2024 in terms of sales

Animal Care is on track to close 2024 on a high note, with sales in the fourth quarter already reaching approximately 1,500 KSEK and projected to surpass 6,000 KSEK for the full year. This highlights the increasing adoption and success of our vetIQure™ TSE system and treatment kits in the veterinary market. A key driver…

Read more

Scandinavian ChemoTech AB (publ) Executive Summary of Interim report Q3 January – September 2024

Third quarter · Net sales amounted to kSEK 1 499 (1 080) · Profit before tax amounted to kSEK -3 243 (-4 526) · Earnings per share amounted to SEK -0,14 (-0,33) · Cash flow from operating activities totaled to kSEK -5 567 (-4 649) Period 1 January - 30 September · Net sales amounted…

Read more

ChemoTech’s Animal Care Enters Strategic Collaboration with Norwegian Veterinary University’s Hospital for Equine Medicine

Scandinavian ChemoTech AB’s subsidiary dedicated to Animal Care has entered a clinical partnership with the Norwegian University of Life Sciences (NMBU) Hospital for Equine Medicine. Following an extensive evaluation period, NMBU’s Equine team, led by Professor and DVM Cathrine Fjordbakk, has decided to integrate ChemoTech’s Tumour-Specific Electroporation (TSE) therapy into their routine treatment offerings. This…

Read more

–

Read all news in English

ChemoTech Videos

2024

Livestream - Scandinavian ChemoTech, vd-intervju (Swedish)

2023

Invest Live | Emissionsaktuella AcuCort & ChemoTech presenterar med Q&A (Swedish)

Redeye Investor Forum - Company Presentation

Clinical strategy update from Medical Director Dr. Suhail Mufti

Redeye Fight Cancer Day 2023 - ChemoTech

2022

ChemoTech 2022 - Mohan Frick CEO summarises the year (Swedish)

ChemoTech Q2 2022 - Livestream Presentation (in Swedish)

SWECARE at EXPO 2020 DUBAI: "Closing Ceremony"

A conversation with Småbolagspodden

(Audio in Swedish)

I det senaste avsnittet av Småbolagspodden berättar Scandinavian ChemoTechs vd Mohan Frick om hur bolagets unika metod för cancerbehandling, via så kallad tumörspecifik elektroporation, ska hjälpa människor och djur världen över.

Lyssna på hela avsnittet här:
52. ChemoTech – Vill vara en kraft för skonsammare cancervård

2021

Presentation of Q3 - Analysera med oss November 2021 (Swedish)

ChemoTech presents for its upcoming Annual General meeting 24 May 2021. Spoken language is Swedish but the presentation is in English.

Innovative TSE technology increases the local effect of chemotherapy (Swedish)

ChemoTech answers questions from the shareholders; Part 1 (Swedish)

CEO Mohan Frick presenting at Erik Penser Bank Bolagsdag (Swedish)

Erik Penser Bank interview with CEO Mohan Frick (Swedish) 8 January 2021

Videos from 2020

Company Presentation of the Q3 report (Swedish) 11th of November 2020

Company Presentation (Swedish) 27th of October 2020

Videos from 2019

Share Day in Gothenburg, November 4 2019 (Swedish)

Videos from 2018

Share analysis ChemoTech Q2 2018 (Swedish)

Share Day in Malmö on May 22, 2018 (Swedish)

Our foundation

Our profound knowledge in electroporation forms the starting point for the company’s existing product and R&D projects: The IQwave™ specially designed for our TSE™ – Tumour Specific Electroporation technology which treats a range of various tumours.
READ MORE

Our research focus

Our aim is to document the effects of elctrochemotherapy for pain management for cancer patients, an area with significant unmet medical need.
READ MORE